Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects-Reference-Cited by-同舟云学术

Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects

Published:2022-09-27 Issue:11 Volume:78 Page:1823-1831
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Murase Katsuyuki,Lee Lucy^ORCID,Ma Jiyuan^ORCID,Barrett Rosemary,Thoolen Martin

Funder

PTC Therapeutics

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00228-022-03393-0.pdf

Reference15 articles.

1. Blankenberg FG, Kinsman SL, Cohen BH et al (2012) Brain uptake of Tc99m-HMPAO correlates with clinical response to the novel redox modulating agent EPI-743 in patients with mitochondrial disease. Mol Genet Metab 107(4):690–699. https://doi.org/10.1016/j.ymgme.2012.09.023

2. Ye L, Stockwell B (2017) Transforming lipoxygenases: PE-specific enzymes in disguise. Cell 171:501–502. https://doi.org/10.1016/j.cell.2017.10.006

3. Joshi YB et al (2015) The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer’s disease. Trends Pharmacol Sci 36(3):181–186. https://doi.org/10.1016/j.tips.2015.01.005

4. Enns GM et al (2012) Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genetics Metab 105(1):91–102. https://doi.org/10.1016/j.ymgme.2011.10.009

5. El-Hattab AW et al (2017) Therapies for mitochondrial diseases and current clinical trials. Mol Genetics Metab 122(3):1–9. https://doi.org/10.1016/j.ymgme.2017.09.009

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone;Clinical Pharmacology in Drug Development;2024-08-12

2. Absorption, distribution, metabolism and excretion of ¹⁴ C-vatiquinone in rats, dogs, and human subjects;Xenobiotica;2023-05-04

3. Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia;Expert Opinion on Investigational Drugs;2023-01-02

4. Clinical Drug‐Drug Interaction Between Vatiquinone, a 15‐Lipoxygenase Inhibitor, and Rosuvastatin, a Breast Cancer Resistance Protein Substrate;Clinical Pharmacology in Drug Development;2022-12-07